Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SUNPHARM Pharmaceuticals (SUNP) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (41)	4/15/1999 8:58:00 AM
From: Graham Marshman	Read Replies (1) \| Respond to of 52

Book sounds good, I'll add it to my list. On the DENSPM for AIDS, it's still in preclin. For valuation model purposes I'm only concerned about market size once it gets to Phase I and later. There is some history of how market cap contribution increases as the moves from Phase I to NDA progresses. Basically modelled as a moving percentage of first year share of potential market. Preclins all get a fixed market cap contribution. The trick with DENSPM for AIDS will be a significant increase in fair valuation once the IND is approved. Graham